SQZ Biotechnologies Company
US ˙ OTCPK ˙ US78472W1045

Introduction

This page provides a comprehensive analysis of the known insider trading history of Marc Schegerin. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Marc Schegerin has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:MORF / Morphic Holding, Inc. CFO and COO 0
US:SQZ / SQZ Biotechnologies Co Director 10,500
US:ARQL / ArQule, Inc. CFO and Treasurer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Marc Schegerin. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SQZB / SQZ Biotechnologies Company - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SQZB / SQZ Biotechnologies Company. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SQZB / SQZ Biotechnologies Company Insider Trades
Insider Sales SQZB / SQZ Biotechnologies Company - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SQZB / SQZ Biotechnologies Company. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SQZB / SQZ Biotechnologies Company Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Marc Schegerin as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-08-20 2024-08-16 4 MORF Morphic Holding, Inc.
Common Stock
D - Sale to Issuer -37,907 0 -100.00
2024-07-10 2024-07-08 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -43,936 37,907 -53.68 55.80 -2,451,629 2,115,211
2024-07-10 2024-07-08 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 43,936 81,843 115.90 15.00 659,040 1,227,645
2024-01-17 2024-01-16 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale -6,041 37,460 -13.89 27.49 -166,071 1,029,802
2024-01-17 2024-01-14 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 4,690 43,501 12.08
2024-01-17 2024-01-13 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 14,675 38,811 60.80
2023-09-08 2023-09-07 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -13,309 24,136 -35.54 54.92 -730,885 1,325,467
2023-09-08 2023-09-07 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -6,691 37,445 -15.16 53.20 -355,964 1,992,089
2023-09-08 2023-09-07 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 20,000 44,136 82.86 15.00 300,000 662,040
2023-04-27 2023-04-25 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -50,000 24,136 -67.44 54.71 -2,735,500 1,320,481
2023-04-27 2023-04-25 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 50,000 74,136 207.16 15.00 750,000 1,112,040
2023-03-09 2023-03-09 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 6,666 23,740 39.04 15.00 99,990 356,100
2023-03-09 2023-03-07 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -50,000 17,074 -74.54 45.00 -2,250,050 768,347
2023-03-09 2023-03-07 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 50,000 67,074 292.84 15.00 750,000 1,006,110
2023-01-18 2023-01-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale -1,670 16,212 -9.34 30.63 -51,150 496,551
2023-01-18 2023-01-14 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 4,690 17,882 35.55
2022-01-19 2022-01-14 4 MORF Morphic Holding, Inc.
Restricted Stock Units (RSU)
A - Award 18,760 18,760
2022-01-19 2022-01-14 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
A - Award 85,632 85,632
2021-11-03 2021-11-02 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
D - Sale to Issuer -6,666 183,934 -3.50
2021-11-03 2021-11-02 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise -6,666 13,192 -33.57 15.00 -99,990 197,880
2021-11-03 2021-11-01 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
D - Sale to Issuer -5,477 190,600 -2.79
2021-11-03 2021-11-01 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -5,477 6,526 -45.63 60.00 -328,620 391,560
2021-11-03 2021-11-01 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 5,477 12,003 83.93 15.00 82,155 180,045
2021-11-03 2021-11-02 4/A MORF Morphic Holding, Inc.
Common Stock
M - Exercise 6,666 13,192 102.15 15.00 99,990 197,880
2021-10-28 2021-10-26 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
D - Sale to Issuer -37 196,077 -0.02
2021-10-28 2021-10-26 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -37 6,526 -0.56 60.00 -2,220 391,560
2021-10-28 2021-10-26 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 37 6,563 0.57 15.00 555 98,445
2021-10-15 2021-10-15 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
D - Sale to Issuer -3,338 196,114 -1.67
2021-10-15 2021-10-15 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -3,338 6,526 -33.84 60.00 -200,280 391,560
2021-10-15 2021-10-15 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 3,338 9,864 51.15 15.00 50,070 147,960
2021-10-15 2021-10-14 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
D - Sale to Issuer -24,184 199,452 -10.81
2021-10-15 2021-10-14 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -24,184 6,526 -78.75 60.02 -1,451,446 391,670
2021-10-15 2021-10-14 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 24,184 30,710 370.58 15.00 362,760 460,650
2021-10-15 2021-10-13 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
D - Sale to Issuer -1,964 223,636 -0.87
2021-10-15 2021-10-13 4 MORF Morphic Holding, Inc.
Common Stock
S - Sale X -1,964 6,526 -23.13 60.00 -117,845 391,576
2021-10-15 2021-10-13 4 MORF Morphic Holding, Inc.
Common Stock
M - Exercise 1,964 8,490 30.10 15.00 29,460 127,350
2021-06-17 2021-06-15 4 SQZ SQZ Biotechnologies Co
Stock Option
A - Award 10,500 10,500
2021-03-09 2021-03-08 4 MORF Morphic Holding, Inc.
Common Stock
P - Purchase 3,000 6,379 88.78 63.50 190,514 405,096
2021-01-19 2021-01-15 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
A - Award 83,000 83,000
2020-10-30 2020-10-29 4 SQZ SQZ Biotechnologies Co
Stock Option
A - Award 42,120 42,120
2020-04-08 3 MORF Morphic Holding, Inc.
Common Stock
4,000
2020-04-08 3 MORF Morphic Holding, Inc.
Common Stock
4,000
2020-04-08 3 MORF Morphic Holding, Inc.
Common Stock
4,000
2020-04-08 2020-04-06 4 MORF Morphic Holding, Inc.
Stock Option (right to buy Common Stock)
A - Award 225,600 225,600
2020-01-16 2020-01-16 4 ARQL ARQULE INC
Stock Option (Right to Buy)
D - Sale to Issuer -230,000 0 -100.00
2020-01-16 2020-01-16 4 ARQL ARQULE INC
Stock Option (Right to Buy)
D - Sale to Issuer -13,000 0 -100.00
2020-01-16 2020-01-16 4 ARQL ARQULE INC
Stock Option (Right to Buy)
D - Sale to Issuer -255,000 0 -100.00
2020-01-16 2020-01-16 4 ARQL ARQULE INC
Common Stock
U - Other -23,001 0 -100.00 20.00 -460,020
2019-12-20 2019-12-18 4 ARQL ARQULE INC
Stock Options (Right to Buy)
M - Exercise -15,000 0 -100.00
2019-12-20 2019-12-18 4 ARQL ARQULE INC
Common Stock
F - Taxes -7,706 22,303 -25.68 20.11 -154,968 448,513
2019-12-20 2019-12-18 4 ARQL ARQULE INC
Common Stock
M - Exercise 15,000 30,009 99.94 2.52 37,800 75,623
2019-06-10 2019-06-06 4 ARQL ARQULE INC
Employee Stock Option (Right to buy)
M - Exercise -10,000 270,000 -3.57
2019-06-10 2019-06-06 4 ARQL ARQULE INC
Common Stock
M - Exercise 10,000 13,039 329.06 2.52 25,200 32,858
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)